Mount Sinai expands cutting-edge molecular testing
... alliance agreement with world-renowned diagnostic company Roche Diagnostics, to establish a Molecular Center of Excellence (MCOE). As a Roche designated MCOE, the Molecular Pathology Laboratory will offer physicians and patients the most advanced molecular diagnostics technologies such as Roche Diagnostics'...Emergency angioplasty patients do best at hospitals where it's the 'default' treatment
...olytic drugs used to treat acute heart attack. The company provided access to the NRMI data at no charge, and approved the study protocol before the analysis. Further information on the study : The patients were treated at 463 hospitals, which the authors divided into four categories. Hospitals in the most...GroPep starts Phase 1 infertility trial
...o US$750million annually. Listed biopharmaceutical company GroPep Limited (ASX:GRO) announcedtoday that it will commence a Phase 1 trial of its infertility drug PV903.The trial, which will be conducted under the Therapeutic Goods AdministrationClinical Trial Notification scheme, was approved by the Royal Ade...Follow-up study shows drug slows severe Alzheimer's symptoms for one year
...ive the drug. The study was paid for by the German company Merz Pharmaceutical GmbH, which markets the medicine in Germany and elsewhere. Forest Pharmaceuticals Inc sells Namenda in the United States. All patients were evaluated with a wide range of tests to assess cognitive and functional abilities, and be...Tercica launches Increlex in the US
...5 submission for marketing approval in the EU, the company is preparing for a potential January 2007 launch o...flicted with severe Primary IGFD. In addition, the company has fully implemented TerciCare, its reimbursement support program that will facilitate the exchange...PlasmaSol, Stevens spin-out, acquired for $17.5 million
PlasmaSol Corporation, a Technogenesis spin-out company founded at Stevens Institute of Technology, has be...eam of grad students joined together and founded a company to commercialize a patented environmental technology invented at the Institute. Six years later, thi...Doctors at UVA health system search for new treatments for diabetic kidney disease
...ine. One drug, called ATL-146e, is licensed to the company Adenosine Therapeutics LLC of Charlottesville, Va. Preliminary results show that this drug prevents inflammation associated with acute kidney injury. "We've been working with drugs affecting the adenosine system in acute kidney injury since the mid-...GroPep completes final milestone of the path malaria vaccine initiative
Adelaide biotechnology company GroPep has completed the manufacture of two vaccin...xpected to start in 2007. Listed biopharmaceutical company GroPep Limited (ASX :GRO) announced today that it had successfully completed the second and final mi...Agreement signed on milk bioactive products
...IMBcom Pty Ltd, the University's commercialisation company for the IMB, has signed this new collaborative research agreement with MG Nutritionals to harness the bioactives of milk in what should be a major step forward in Australian biodiscovery. CEO of IMBcom Dr Peter Isdale said the agreement set the foun...GroPep to pursue promising asthma drug following preclinical study results
Adelaide biotechnology company GroPep has completed preclinical efficacy studies ...-cell peptide technology. Listed biopharmaceutical company GroPep Limited (ASX: GRO) announced today that it had completed testing of its T-cell peptide drug c...Visually impaired people prefer to watch television enhanced with special processing
...eo for normal sighted TV viewers. *DigiVision, the company that developed the Belkin device and holds a patent pending on the technology, is interested in creating another version of the product for visually impaired viewers based on results from this and other image studies by Peli and his colleagues,*(Digi......rams and added field support which would allow the company to carefully expand the number of European hospitals implanting the VentrAssist LVAD. Ventracor's CE Mark Trial is aimed at obtaining approval to sell the VentrAssist TM in the major market of Europe. Dr Sutton added Ventracor continued to focus o...Carnegie Mellon, Pitt demo technology to help elderly at CAST exhibition in Washington
...o participate. Blueroof Technologies, a non-profit company building inexpensive, modular, smart homes will sh...hat included the Carnegie Mellon and Pitt spin-off company AT Sciences. "The technologies we are bringing to the conference will allow the elderly to continue...Magnet lab researcher exploring science behind commercial applications of liquid helium
...Tallahassee. Van Sciver is working with technology company Oxford Instruments on the first phase of a grant t...nager with Oxford Instruments, a global technology company that provides tools and systems for the physical science and bioscience sectors. "Through our partne...Australians of the year forge partnership for burns drug development
...as been developed by Phylogica, the first spin out company from the Telethon Institute for Child Health Research, headed by Professor Fiona Stanley. Phylogica announced to the Australian Stock Exchange today that it has signed a development agreement with the McComb Foundation, headed by burns specialist and...Institute for OneWorld Health receives multimillion dollar grant
...neWorld Health, the first nonprofit pharmaceutical company in the U.S., today announced that it has received ...nd Pharma Ltd., a U.S. FDA-approved pharmaceutical company specializing in injectable drugs based in Hyderabad, India. Gland has agreed to manufacture paromomy...Can healthcare systems afford Herceptin for early breast cancer?
... extra costs for the health gains. "Even after the company has set its price at a level acceptable to them an...well and maximise health gains. The pharmaceutical company wants its product to be reimbursed for a large population in order to sell large volumes. So, the ai...Higher dose formulation of FOSRENOL approved to reduce serum phosphorus in esrd patients
... is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system (CNS), gastrointestinal (GI), general products (GP) and human genetic therapies (HGT) -- all being areas in which Shire has a commerc...Strategic plan to accelerate Australian drug development
... and operating through UQ's main commercialisation company UniQuest Pty Ltd, TetraQ was designed to provide a "one-stop-shop" for pre-clinical drug development in Australia. Australia's pre-clinical drug development capability is limited or fragmented, so most Australian companies contract the bulk of their......ity of Newcastle upon Tyne, together with Canadian company Genesis Genomics. It is being offered via branches of the Court House Clinics, which are based across the country in London, Essex, Sussex, Birmingham and, to come soon, in Manchester, and by the BUPA clinic in Washington, Tyne and Wear (these place...